Compare iShares MSCI Australia ETF (EWA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Summit Therapeutics Inc — how do they compare? iShares MSCI Australia ETF trades at $28.51 (market cap $1.17B), while Summit Therapeutics Inc trades at $17.3 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 11.7× iShares MSCI Australia ETF's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Summit Therapeutics Inc for 16 Days on average.
| EWA | SMMT | |
|---|---|---|
Market Cap | $1.17B | $13.71B |
Volume | 2,121,231 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $26.38 |
52-Week Low | $24.95 | $12.43 |
Typical Hold Time | 63 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.465, up 0.83% today, but technical indicators signal a bearish trend with all moving averages in sell territory. The ETF, which tracks Australian equities, faces headwinds from domestic market volatility and inflation concerns, as Australian shares recently hit a three-month low. Key support and resistance cluster tightly around $28, indicating a critical price zone. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and macroeconomic pressures, though some analysts see upside potential from commodity exposure. Risks include persistent inflation, tight monetary policy, and global economic shifts. Investors should weigh the bearish technicals against Australia's resource-driven economic prospects.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
